CannBioRx Life Sciences Corp Total Liabilities
CannBioRx Life Sciences Corp total liabilities. Based on the latest financial reports, CannBioRx Life Sciences Corp (ATNFW) has total liabilities worth $5.33 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CannBioRx Life Sciences Corp (ATNFW) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CannBioRx Life Sciences Corp (2016–2024)
Total liabilities of CannBioRx Life Sciences Corp from 2016 to 2024. This chart illustrates how CannBioRx Life Sciences Corp's total liabilities have evolved over time, based on quarterly financial data.
CannBioRx Life Sciences Corp Competitors by Total Liabilities
The table below lists competitors of CannBioRx Life Sciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tipco Asphalt Public Company Limited
F:TPY1
|
Germany | €8.15 Billion |
|
Ellies
JSE:ELI
|
South Africa | ZAC294.11 Million |
|
NEW FRONTIER VENT. INC.
F:S1O
|
Germany | €570.98K |
|
Mirriad Advertising PLC
LSE:MIRI
|
UK | GBX1.52 Million |
|
PureCycle Technologies Inc
NASDAQ:PCTTW
|
USA | $920.90 Million |
|
Milton Capital PLC
LSE:MII
|
UK | GBX61.88K |
|
Polyplex (Thailand) Public Company Limited
F:PKW
|
Germany | €5.63 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down CannBioRx Life Sciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of CannBioRx Life Sciences Corp.
Liquidity & Leverage Metrics
CannBioRx Life Sciences Corp Total Liabilities Ratios Explained
CannBioRx Life Sciences Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CannBioRx Life Sciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CannBioRx Life Sciences Corp (2016–2024)
The table below shows the annual total liabilities of CannBioRx Life Sciences Corp from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.51 Million | -34.82% |
| 2023-12-31 | $5.39 Million | -35.14% |
| 2022-12-31 | $8.31 Million | -64.49% |
| 2021-12-31 | $23.39 Million | -7.35% |
| 2020-12-31 | $25.25 Million | +89.63% |
| 2019-12-31 | $13.31 Million | +191.26% |
| 2018-12-31 | $4.57 Million | +7.98% |
| 2017-12-31 | $4.23 Million | +1840.82% |
| 2016-12-31 | $218.11K | -- |
About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more